Samuel Chan -
1. Daratumumab therapy addition to bortezomib, cyclophosphamide, and dexamethasone showed improved cancer response in patients with systemic immunoglobulin light-chain amyloidosis. 2. The daratumumab group presented with an increase in serious adverse events such as lymphopenia, cardiac failure, and infections. Evidence Rating Level: 1 (Excellent) Study Rundown: Immunoglobulin light-chain amyloidosis (AL) is a...
#VisualAbstract GIMEMMA-MMY-3006: Bortezomib, Thalidomide, and Dexamethasone (VTD) Followed By Stem-Cell Transplantation Improves Long-Term Survival Outcomes in Newly Diagnosed Multiple Myeloma (MM)Kathleen Lau -
Check out the original article from the Lancet Haematology here.
12Page 1 of 2